Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Trodelvy
Pharma
Gilead's CAR-T sales stagnate as Trodelvy takes another write-off
Gilead's CAR-Ts Yescarta and Tecartus have stayed relatively flat all year with Yescarta facing a 1% decline over the third quarter.
Zoey Becker
Nov 7, 2024 11:16am
Gilead pulls Trodelvy in bladder cancer after trial flop
Oct 18, 2024 10:18am
Gilead unfolds Trodelvy triplet's first-line NSCLC data
Sep 9, 2024 1:45pm
Merck, AstraZeneca, Gilead: The race for supremacy in an ADC field
Aug 2, 2024 4:00pm
ASCO: Gilead seeks silver lining in Trodelvy’s failed NSCLC trial
May 31, 2024 8:00am
Gilead's Trodelvy suffers double whammy
May 30, 2024 6:20pm
